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Abstract
Over the last years there has been an increased focus on the importance of knowing the effect of pre-analytical influence on
the proteomes under study, particularly in the field of biomarker discovery. We present three proteomics studies examining
the effect of blood contamination and the rostro-caudal gradient (RCG) on the cerebrospinal fluid (CSF) proteome, in
addition to plasma/CSF protein ratios. The studies showed that the central nervous system (CNS) derived proteins appeared
to be unaffected by the RCG, while the plasma-derived proteins showed an increase in concentration towards the lumbar
area. This implies that the concentration of the plasma-derived proteins in CSF will vary depending on the volume of CSF
that is collected. In the CSF samples spiked with blood, 262 of 814 quantified proteins showed an abundance increase of
more than 1.5 fold, while 403 proteins had a fold change of less than 1.2 and appeared to be unaffected by blood
contamination. Proteins with a high plasma/CSF ratio appeared to give the largest effect on the CSF proteome upon blood
contamination. The results give important background information on how factors like blood contamination, RCG and
blood-CNS-barrier influences the CSF proteome. This information is particularly important in the field of biomarker
discovery, but also for routine clinical measurements. The data from the blood contamination and RCG discovery studies
have been deposited to the ProteomeXchange with identifier PXD000401.
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Introduction
Protein quantification in human body fluids is of high interest in
clinical proteomics, and pre-analytical factors may influence the
quantitative analysis of the proteome. Knowledge about which
and how proteins are affected is important for sample selection
and enables exclusion of samples with inadequate quality.
Cerebrospinal fluid (CSF), an ultra-filtrate of plasma produced
in the choroid plexi, is the most proximal fluid to the central
nervous system (CNS) and an important material in the search for
biomarkers in neurological diseases. The effect of the pre-
analytical influence on the human CSF proteome has previously
been studied using proteomics [1-4].
Blood contamination is one of the most important pre-analytical
factors in CSF analysis. CSF becomes blood contaminated in up to
20% of all lumbar punctures (LP) [5] and due to the high protein
concentration in blood, only a small fraction of blood leakage into
the CSF will affect the protein concentration, particularly the
concentration of blood-derived proteins [5,6]. Peroxiredoxin,
catalase, carbonic anhydrase-I and hemoglobin were found to be
blood-contamination specific proteins by You et al. [6]. They also
suggested that proteases present in blood could cause degradation
of CSF proteins in blood contaminated samples. Furthermore,
blood proteins have been reported to cause suppression of ion
signals in matrix-assisted laser desorption/ionization (MALDI)
peptidome analysis of CSF, but this can be reduced by
centrifugation of CSF before initial freezing [3,7]. The general
guidelines for selecting high quality CSF recommends to eliminate
samples with .500 erythrocytes/mL [4].
As the CSF flows uni-directionally along the spinal cord down
to the lumbar subarachnoid space [8], passive diffusion creates a
protein concentration gradient from the ventricles to the lumbar
area, referred to as the rostro-caudal gradient (RCG). It has been
reported that blood-derived proteins such as serum albumin
increase down the gradient with up to 2.5 fold change [9,10] and
that proteins that origin from the brain such as NSE, S-100B and
tau protein decrease linearly in concentration downwards the
RCG [11]. Proteins released from the leptomeninges into the
subarachnoid space (prostaglandin-H2 D-isomerase, cystatin-C),
have been reported to increase in concentration along the RCG,
due to higher local concentration in the surrounding leptomenin-
ges than in the CSF. The concept of a decrease in brain proteins
was very recently analyzed by Brandner et al. [12] where they
analyzed concomitant ventricular and lumbar CSF without
confirming the trend described by Reiber [9]. Because of the
RCG effect, the protein concentration is higher in the lumbar area
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than in the ventricular area and due to this it has been
recommended to collect a standard volume of CSF during LP
[9,13,14]. The RCG effect in human CSF has been presented in
several studies [9,11,12,15-19], but in none using a large-scale
proteomics study as presented in this paper.
In the present study, we have examined the effect of blood
contamination on the CSF proteome by monitoring the
abundance of more than 800 CSF proteins at two different blood
spike-in levels through a sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) LC-MS approach. We also
monitored the effect of centrifugation on blood-spiked CSF
samples in a related experiment. In a separate experiment, we
examined the RCG effect on the CSF proteome using iTRAQ
(isobaric tags for relative and absolute quantitation) shotgun
proteomics. Multiple reaction monitoring (MRM) MS in combi-
nation with stable isotope dilution (SID) was used to monitor 48
proteins derived from blood or CNS (leptomeninges and brain).
For this experiment we analyzed CSF from the 2nd to the 45th mL
of CSF from one patient with progressive supranuclear palsy (PSP)
undergoing LP. In the last experiment, the plasma/CSF ratio was
calculated for 152 proteins in five individuals using dimethyl
shotgun proteomics. The presented work will be particularly
important for quantitative protein measurements in CSF and
provides important results for the understanding of the RCG and
blood/CSF protein relation.
Materials and Methods
Sample collection and handling
CSF was collected from patients undergoing diagnostic LP at
the Department of Neurology, Haukeland University Hospital,
Bergen, Norway. CSF used in analysis of the CSF/plasma protein
ratio was collected from patients undergoing spinal anesthesia at
the Department of Orthopedic surgery, Haukeland University
Hospital, Norway. The CSF was collected and treated after the
guidelines presented in the consensus protocol if not stated
otherwise [4]. The plasma samples were collected in K2 EDTA
tubes and centrifuged at 4uC at 11006g for 10 min. Plasma and
CSF was collected at the same time. All CSF and plasma samples
went through one freeze/thaw cycle. In the blood contamination
study we used fresh blood donated by a healthy volunteer.
Ethics statement
The study was approved by The Regional Committee for
Medical and Health Research Ethics (REC), Western Norway,
and written informed consent was obtained from all patients and
controls.
Experimental design
The pre-analytical factors we have studied are: Blood contam-
ination of CSF, the RCG of CSF proteins, and plasma/CSF
protein ratio (Figure 1).
In the iTRAQ shotgun experiment (Figure 3), 577 proteins were
identified (data not shown) of which 279 proteins were quantified
with at least two peptides in all experiments (Table S4). Table 1
shows the criteria for distinguishing the effect of the RCG, using
the same rational as for the blood contamination study. In
addition, we used the R-squared value criteria for selection based
on the rational that proteins truly affected by the RCG would
show certain linearity in concentration change along the gradient.
An R-squared value of .0.7 was considered to reflect sufficient
linearity, and in combination with a fold change above 1.5, such
proteins were considered to have a measurable quantitative
change related to the RCG. By using these criteria we found that
60 proteins were affected by the RCG. For 120 proteins it was
difficult to determine whether or not they were affected and these
proteins were therefore regarded as uncertain. For the remaining
99 proteins we could not measure any effect of the RCG and they
were termed unaffected. Plasma proteins were highly represented
among the proteins which increased in concentration towards the
lumbar area. Between RCG point 1 and 7 the plasma proteins
albumin and haptoglobin had a fold change increase of 1.58 and
1.79. Hemoglobin beta had a fold change of 12.68 between RCG
point 1 and 7, but only 1.19 between RCG point 2 and 7. The
high abundance of hemoglobin beta in RCG point 1 reflects the
high number of erythrocytes (37 000/mL) in the 0-1st mL sample,
which was used for routine analysis and thus not included in our
dataset. Among the proteins unaffected by the RCG were mainly
proteins expected to predominantly arise from the CNS, like
cystatin-C and contactin-1, whereas in the uncertain category we
found a mixture of both blood- and CNS-derived proteins.
Chemicals
Urea, dithiothreitol (DTT), iodoacetamide (IAA), N-octyl-b-D-
glucopyranoside (NOG) and calcium chloride were purchased
from Sigma-Aldrich (St. Louis, MS, USA). Trypsin Porcine was
purchased from Promega. Tris (hydroximethyl) amonimethane
was from Merck KGaA (Darmstadt, Germany). Water, acetoni-
trile (ACN) and formic acid (FA) were MS grade, purchased from
Fluka Analytical, Sigma-Aldrich. The iTRAQ kit was purchased
from AB SCIEX (Framingham, MA, USA). 4-12% Bis-Tris gel
(NuPAGEH), MES SDS Running Buffer, lithium dodecyl sulfate
(LDS) sample buffer, and SeeBlue Plus2 Pre-Stained Standard
were from Invitrogen, Life Technologies (Carlsbad, CA, USA).
Stable Isotope Standards (SISs) were in crude quality unless stated
otherwise, and were purchased from Thermo Fisher Scientific
(Ulm, Germany) and JPT Technologies (Berlin, Germany). Their
C-terminal lysine or arginine was labeled with 13C and 15N.
Formaldehyde-d2 (CD2O) (98% D, 20 wt %),
13CD2O (99%
13C,
98% D, 20 wt %), and sodium cyanoborodeuteride (96% D) were
from Isotec (Miamisburg, OH, USA).
Analysis of total protein concentration
Total protein concentrations for all samples were measured
using QubitTM Fluorometer (Life Technologies).
The blood contamination study
CSF samples with ,500 erythrocyte/mL were chosen for the
blood contamination experiments. Hemoglobin beta was not
detected in any of the CSF samples using SID-MRM (data not
shown). One mL CSF from four patients were pooled and divided
into four aliquots. One aliquot (1 mL) was kept as reference CSF
without added blood, one was spiked with 20 mL blood/mL CSF
(2%) and two were spiked with 5 mL blood/mL CSF (0.5%). The
sample spiked with 2% blood and one of the samples spiked with
0.5% blood were centrifuged at 4uC at 4006g for 10 min. The
samples were analyzed in experiment A (SDS-PAGE label-free)
and B (in-solution label-free) with experimental setup as shown in
Figure 2.
Experimental workflow experiment A. CSF was protein
depleted according to the manufacturer’s protocol using the
Multiple Affinity Removal System (MARS-HU-14) 4.66100 mm
LC column (Agilent Technologies, CA, USA) coupled to Dionex
Ultimate 3000 LC system (Thermo Scientific, Bremen, Germany).
The total protein amount ranged from approximately 500-
1400 mg prior to depletion due to different amount of added
blood. When depleting five identical aliquots from the same
sample, the %CV of the measured protein concentration over all
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samples was 6.8%. The protein depleted CSF was concentrated
using 3 kDa ultra-centrifugation filters (Amicon Ultra-4, Millipore,
Bedford, MA) which were pre-rinsed with 0.1% NOG for
increased protein recovery, and freeze dried. The pellet was
dissolved in 2X LDS sample buffer (NuPAGE, Invitrogen),
reduced with 10 mM DTT and alkylated with a final concentra-
tion of 20 mM IAA for 20 min in darkness before the samples
were loaded on 4-12% gradient Bis-Tris gels (NuPAGE Invitro-
gen, Life Technologies). Each lane was cut into ten fractions which
were washed, trypsin digested, and peptide eluted essentially as
described elsewhere [20]. All fractions resulting from the
extraction of peptides were combined in the elution plate and
freeze dried. The dry peptide mixtures were re-suspended in 0.1%
FA and loaded onto a pre-column (Dionex, Acclaim PepMap
Nano Trap column, C18, 75 mm i.d.62 cm, 3 mm) followed by
separation on the analytical column (Dionex, Acclaim PepMap100
LC nano column, 75 mm615 cm, C18, 2 mm) using a Dionex
Ultimate 3000 rapid separation (RS) LC nano system (Thermo
Scientific) coupled online to an Orbitrap Velos Pro mass
spectrometer (Thermo Scientific, Bremen, Germany). A 90 min
LC-method with a gradient composition of mobile phase A (0.1%
FA/2% ACN) and mobile phase B (0.1% FA/90% ACN) was
used. The gradient was as follows: 5% B from 0-6 min, increasing
to 8% B from 6-6.5 min, 8-38% from 6.5-67 min, then 38-90% B
from 67-70 min. Hold at 90% B for 5 min, and ramp the gradient
Figure 1. Overview of the conducted studies. Blood contamination: in experiment A protein depleted CSF was separated by SDS-PAGE, in
experiment B crude CSF was in-solution digested. Progenesis LC-MS was used for data analysis. In the rostro-caudal gradient study, we used iTRAQ-
labeling with mixed mode reversed phase-anion chromatography (MM (RP-AX)) fractionation. The Spectrum Mill software was used for data analysis.
For verification we used stable isotope dilution (SID) multiple reaction monitoring (MRM) to monitor 70 peptides. MM (RP-AX) chromatography was
used for fractionation and the MultiQuant software was used for data analysis. In the plasma/CSF ratio study equal amount of corresponding CSF and
plasma from five patients were compared using dimethyl labeling. Samples were fractionated using strong cation exchange (SCX) chromatography.
Proteome discoverer was used for data analysis. For all discovery experiments the samples were analyzed on an Orbitrap Velos Pro and for SID-MRM
the samples were analyzed on a Q-trap 5500. SIS = Stable Isotope Standards
doi:10.1371/journal.pone.0090429.g001
Table 1. Categorization of proteins in the rostro-caudal
gradient study.
Fold change R-square Definition # Proteins
$ 1.5 . 0.7 Affected 60
, 1.5 . 0.7 Uncertain 41
. 1.2 0.3-0.7 Uncertain 79
, 1.2 0.3-0.7 Unaffected 44
, 0.3 Unaffected 55
Fold change and R-squared limits for defining proteins quantified in the rostro-
caudal gradient (RCG) iTRAQ experiment as affected, uncertain or unaffected by
the gradient. The fold change and R-squared limit is calculated between the 1-
2nd and 44-45th mL of CSF, referred to as RCG point 1 and 7.
doi:10.1371/journal.pone.0090429.t001
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Figure 2. Flow chart of the blood contamination studies. Cerebrospinal fluid (CSF) from four patients (P1-P4) were pooled and divided into
aliquots which were spiked with different amounts of blood. In experiment A, a reference sample was compared to CSF spiked to achieve 0.5% and
2% blood. The CSF samples were centrifuged, protein depleted, and separated by SDS-PAGE into ten fractions per lane. In experiment B, we
examined the effect of centrifugation. A reference sample was compared to two CSF samples spiked to achieve 0.5% blood, where one of the blood
contaminated samples was not centrifuged. The samples were trypsin digested in-solution. All samples were analyzed on an OrbiTrap Velos Pro.
doi:10.1371/journal.pone.0090429.g002
Effect of Pre-Analytical Factors on CSF Analysis
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e90429
from 90-5% B from 75-78 min. Hold at 5% B for the last 12 min.
The peptides were eluted at a flow rate 280 nL/min. The mass
spectrometer was operated in the data-dependent-acquisition
mode to automatically switch between full scan MS and MS/
MS acquisition. Instrument control was through Tune 2.7 and
Xcalibur 2.2.
Survey full scan MS spectra (from 300 to 2000 m/z) were
acquired for 80 min in the Orbitrap with a resolution R = 60 000
at 400 m/z (after accumulation to a target value of 1e6 in the linear
ion trap with maximum allowed ion accumulation time of
500 ms). The seven most intense eluting peptides above an ion
threshold value of 1000 counts, and charge states $ +2, were
sequentially isolated to a target value of 1e4 (maximum accumu-
lation time was 200 ms) and fragmented in the high-pressure
linear ion trap by low-energy CID (collision-induced-dissociation)
with normalized collision energy of 40% and wideband-activation
enabled. The isolation width was maintained at 2 Da, activation
q = 0.25, and activation time of 10 ms. The resulting fragment
ions were scanned out in the low-pressure ion trap at normal scan
rate, and recorded with the secondary electron multipliers. One
MS/MS spectrum of a precursor mass was allowed before
dynamic exclusion for 20 s. Lock-mass internal calibration was
not enabled. The raw files were analyzed and pre-processed using
the Progenesis LC-MS software 2.7 (Nonlinear Dynamics, New-
castle, UK). The MS/MS spectra were analyzed using the
database homo sapiens SwissProt (downloaded April 2012, 40 486
entries) using the open-source graphical user interface SearchGUI
(version 1.7.3) [21], with search engines OMSSA (2.1.9) and
X!Tandem (Cyclone, (2010, 12.01.1)) [22,23]. The following
search parameters were used; 10 ppm parent ion tolerance, 0.7 Da
fragment mass tolerance, carbamidomethylation of Cys as fixed
modification, oxidation of Met as variable modification, and two
missed cleavages were allowed. The peptides were assembled to
proteins using PeptideShaker (version 0.14.7) (http://peptide-
shaker.googlecode.com), and filtered at the stringent threshold of
1% false discovery rate (FDR). The FDR was estimated using the
reversed version of the database [24]. Identification results were
further processed in the Progenesis software to generate a protein
report. The protein report was generated with no protein grouping
and quantification was based on non-conflicting features, which
means that only unique peptides contributed to quantification.
Experimental workflow experiment B. CSF was in-
solution digested according to the protocol in Document S1 and
analyzed and quantified as described for Experiment A.
The rostro-caudal gradient experiment
To detect a possible RCG of proteins we sampled the seven
following points of the RCG from a PSP patient: 1-2nd, 10-11th,
16-17th, 24-25th, 31-32nd, 38-39th and 44-45th mL CSF, referred to
as RCG point 1-7, respectively. The CSF was centrifuged at
20006g for 10 min, and stored at -80 uC. The protein
concentration varied from 0.675-0.414 mg/mL between RCG
point 1 and 7 (lumbar to ventricular area). The 0-1st mL was blood
contaminated (erythrocytes 37 000/mL); this one mL was used for
routine analysis and was not included in this study. The workflow
for the RCG experiment is shown in Figure 1.
iTRAQ discovery. In the iTRAQ discovery experiment
equal volumes representing the seven RCG points were processed
as shown in the experimental setup in Figure 3. The three
reference samples were identical and contained equal volumes of
the seven RCG points. The first and seventh RCG points were
included twice in the experimental design. The twelve samples
(Figure 3) were dried, re-suspended, and trypsin digested using the
iTRAQH Reagent 4plex Applications Kit according to the
vendor’s protocol with one exception: 1/3 of the iTRAQ
Dissolution Buffer and 1/3 of the iTRAQH reagents were used
for each experiment (n = 3).
The combined and labeled tryptic peptides were dried and
fractionated by mixed mode reversed phase-anion exchange (MM
(RP-AX)) chromatography on a 1260 Infinity LC system (Agilent,
Santa Clara, CA, USA) using a Promix MP column
(1.0 mm6250 mm, 5mm, 300 A˚) (SIELC Technologies, IL,
USA). The duration of the gradient was 70 min, with 50 mL/
min flow, using the following buffers: Buffer A (20 mM
ammonium formate/3% ACN, pH 6.5) and Buffer B (2 mM
ammonium formate/80% ACN, pH 3.0). The dry peptide
mixture was re-suspended in Buffer A and fractionated into 21
fractions with the following gradient: Hold at 15% B from 0-
10 min. From 10-45 min 15-60% B, from 45-55 min 60-100% B,
hold at 100% B from 55-60 min, and ramp from 100-15% B from
60-65 min, then hold at 15% B from 65-70 min. The fractions
were freeze-dried and re-suspended in 0.1% FA before injection
on the Orbitrap system. MM (RP-AX) fractions 1-4 were
excluded, as they were found to contain excess iTRAQ reagents,
and the two latest fractions were combined before injection.
Approximately 0.5 mg of each MM (RP-AX) fraction was
loaded on an Ultimate 3000 RSLC nano system online connected
to an Orbitrap Velos Pro using the same settings and columns as
described for the blood contamination study. The seven most
intense eluting peptides above an ion threshold of 1000 counts and
charge states $ +2, were sequentially isolated in a back-to-back
analysis of the same precursors using two different fragmentation
techniques, CID and HCD (higher-energy collision dissociation).
The CID fragmentation was performed as described for the blood
contamination study except collision energy of 35% compared to
40%. For the HCD fragmentation, the ions were isolated in the
high-pressure linear ion trap to a target value of 5e5 at a maximum
allowed accumulation time of 1000 ms and isolation width at
3 Da. Fragmentation in the HCD cell was performed with a
normalized collision energy of 40%, and activation time of 0.1 ms.
Fragments were detected in the Orbitrap at a resolution of 7500
with first mass fixed at m/z 160. Two MS/MS spectra of a
precursor mass were allowed before dynamic exclusion for 10 s,
and lock-mass internal calibration was not enabled.
The generated raw files were extracted, searched and validated
using the Spectrum Mill software package v4.0 beta (Agilent
Technologies, Santa Clara, CA, USA). The data extraction
settings were as follows: Fixed modifications were methyl
methanethiosulfonate (MMTS) of Cys and iTRAQ (N-term,
Lys), variable modifications were oxidation of Met, fragment mass
tolerance MH+ interval 300-4000, scan time range 0-300 min,
and sequence tag length .0. Merge CID and HCD MS/MS, and
find precursor 12C with maximum charge 7. The resulting data
were searched against the homo sapiens SwissProt database
(downloaded August 2010, containing 20 286 entries) with
following search parameters: Precursor mass tolerance 10 ppm
and fragment mass tolerance 0.7 Da, maximum two missed
cleavages allowed, and MMTS (Cys) and iTRAQ (N-term, Lys) as
fixed modifications. Reverse database scores were calculated. The
default fixed auto validation settings were applied for both proteins
and peptides, including calculate FDR using reverse hits. In
protein mode, the threshold score was .20, proteins were
accepted at precursor charge +2 if score .6, Scored Percent
Intensity .60%, delta rank1-rank2 .2, and at charge +3 if .8,
.70%, .2. The FDR was ,1%. The first and seventh RCG
points were included twice in the experimental design and the
average protein abundances were reported. In Spectrum Mill, a
ratio was calculated for every protein by dividing the protein
Effect of Pre-Analytical Factors on CSF Analysis
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abundance in an individual RCG sample by the abundance in the
reference sample. Using these ratios, we calculated the R-squared
value and the fold change values for every protein between the
different RCG points.
SID-MRM verification in the RCG study. To verify the
findings from the RCG iTRAQ discovery, MRM assays were
built. Equal volumes of CSF from the seven RCG points were
reduced, alkylated and trypsin digested according to the protocol
available as Document S1. The SIS mixture was added to the
digest with concentrations corresponding to the endogenous
peptides and desalted with the Oasis HLB mElution 96 well plate
(Waters, Milford, MA) as described in [25]. The spiked CSF
digests were divided into seven fractions using MM (RP-AX) with
the same LC gradient as for the iTRAQ-labeled RCG samples.
The samples were re-suspended in 3% ACN/5% FA, and equal
volumes of each sample (ranging from 0.6-1 mg) were analyzed on
a triple quadrupole tandem mass spectrometer (Q-TRAP 5500
(AB SCIEX, MA, USA)) online coupled to a Dionex Ultimate
3000 RSLC nano system. The spiked CSF digest was loaded onto
the pre-column and analyzed using the same MS settings and LC
gradient as described elsewhere [25]. The final MRM assay
contained 70 peptides corresponding to 48 proteins, and at least
three transitions were monitored for each peptide. The most
intense transition free of interference was used for quantification.
The complete list of proteins, peptides, Q1 and Q3 values and
parameter settings is available in Table S1. The MRM data were
analyzed in MultiQuant 2.0.2 (AB SCIEX) using the same settings
as described previously [25]. To detect possible interference, a
fractionated CSF test sample was run three times and analyzed
using the open-source software AuDIT [26]. The % coefficient of
variance (CV) of the pipeline system was found to be ,20 by
analyzing an unfractionated CSF sample as quality control
between every seventh sample (data not shown). The ratio
between the SIS and endogenous peptide was calculated as
previously described [25]. This ratio was used to calculate the fold
change and the R-squared value for all the included proteins
across the seven different points in the RCG.
The plasma/CSF protein ratio experiment
To investigate the plasma/CSF ratio for a larger number of
proteins we collected corresponding plasma and CSF from five
patients undergoing surgery using spinal anesthesia. These patients
had no neurological history and did not have any inflammatory
diseases. None of the CSF samples had visible amounts of blood,
and hemoglobin beta was not detected by SID-MRM. The
abundance of proteins present in both plasma and CSF were
quantified using dimethyl labeling. A reference mix was prepared
of total 10 mg protein from both plasma and CSF from each of the
five patients. The individual samples were digested and labeled as
shown in Figure 4. The digestion and labeling protocol is
described elsewhere [27]. The samples were analyzed using the
Orbitrap Velos Pro as explained for the blood contamination
Figure 3. Flow chart of the rostro-caudal gradient study. In the rostro-caudal gradient (RCG) study, we examined the seven following points of
the RCG from a PSP patient: 1-2nd, 10-11th, 16-17th, 24-25th, 31-32nd, 38-39th and 44-45th mL CSF, referred to as RCG point 1-7, respectively. Twelve
samples were digested and iTRAQ labeled (114-117). A reference, (labeled with iTRAQ reagent 114) containing the same amount of each RCG point,
was included in each experiment. The RCG points 1 and 7 were included twice. After digestion and iTRAQ-labeling, samples were combined as
follows: Exp. 1 (reference, 44-45th mL, 24-25th mL and 1-2nd mL), Exp. 2 (reference, 1-2nd mL, 38-39th mL and 16-17th mL), and Exp. 3 (reference, 10-11th
mL, 44-45th mL and the 31-32nd mL). The three experiments were fractionated by mixed mode reversed phase-anion chromatography (MM (RP-AX))
and analyzed on an Orbitrap Velos Pro. The protein abundances were averaged for each protein in the duplicate samples.
doi:10.1371/journal.pone.0090429.g003
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study, with some exceptions. A 50 cm analytical column (Acclaim
PepMap 100, 50 cm675 mm i.d. nanoViper column, packed with
3 mm C18 beads) was used, and the gradient composition was 5-
8% B over 1 min, then 8–35% B over 134 min followed by 35–
90% B over 15 min. Elution of very hydrophobic peptides and
conditioning of the column were performed during 15 min
isocratic elution with 90% B and 20 min isocratic elution with
5% B, respectively. The raw files were analyzed patient vice in
Proteome discoverer 1.3 (Thermo, Bremen, Germany) using the
following work flow: From spectrum files to event detector and
precursor ions quantifier for quantification and spectrum files to
spectrum selector, Mascot and Perculator for identification by
searching against the reviewed SwissProt homo sapiens (downloaded
January 2013, 20 226 entries). The following settings were used:
Carbamidomethylation of Cys as fixed modification, oxidation of
Met as variable. 10 ppm for precursor and 0.7 Da for fragment
tolerance, two missed cleavages were allowed, and FDR was set to
1%. Only unique peptides were used for quantification and only
proteins with two or more peptides in two or more patients were
included. The abundance of every protein was calculated in every
sample by Proteome Discoverer, and a ratio was calculated by
dividing the abundance in the plasma sample by the abundance in
the corresponding CSF sample. This ratio was used to calculate an
average ratio and a %CV for every protein across the five
individuals.
Results
Effect of blood contamination
To investigate how blood contamination affects the CSF
proteome, a reference CSF sample was compared to CSF spiked
to achieve 0.5% and 2% blood (experiment A, Figure 2). A total of
1869 proteins were identified and 814 proteins were quantified
with two unique peptides or more (Table S2). Even though the
samples were protein depleted, small levels of albumin, fibrinogen,
apolipoprotein AI and AII, complement 3 and transthyretin
remained in the sample. Their quantitative data were omitted
from the results.
The quantitative information for the 814 proteins for the two
comparisons (1) reference versus 0.5% blood and (2) reference
versus 2% blood, are given in Table S2. The 262 proteins with an
abundance increase of 1.5 fold in either of the two spike-in levels
were defined as affected by the blood contamination, while 403
proteins had a fold change of less than 1.2 in both experiments and
were defined as not affected. The 149 proteins with observed fold
changes between 1.2 and 1.5 were defined as uncertain with
respect to being affected by the blood contamination. A protein
abundance change of less than 20% is difficult to detect with the
semi-quantitative methods applied as the technical variance is
considered to be at least 20%. Hence, all proteins with less than
20% abundance change in our dataset were termed ‘‘unaffected’’.
The proteins with an abundance change of more than 50% are
considered highly likely to be affected by the blood contamination,
even though false positives cannot be ruled out. These proteins
were termed ‘‘affected’’. When there is an observed fold change of
20-50%, it is difficult to determine whether a protein is affected by
the added blood or if the observed change is due to technical
inaccuracies. Hence, this category was termed ‘‘uncertain’’.
Naturally, there were many known blood-proteins among the
affected proteins. The most affected proteins appeared to be those
associated to, or found in red blood cells, platelets or other larger
components in blood. Examples of such proteins are purine
nucleoside phosphorylase (123 increase in fold change), platelet
factor 4 (57 increase in fold change) and apolipoprotein C-II (51
increase in fold change). For proteins secreted by the liver, a
typical four fold increase was observed in the CSF sample spiked
to achieve 2% blood (complement factor H (3.98), plasma
kallikrein (4.43) and serum amyloid A-4 protein (4.61)). In the
unaffected group we found as expected mainly CNS derived
proteins.
Figure 4. Flow chart of the plasma/CSF study.We compared the cerebrospinal fluid (CSF) and plasma protein ratio of five patients (P1-P5) using
dimethyl labeling. The reference sample was a mix of equal total amount of CSF and plasma, and was labeled by light reagents. The five CSF samples
were labeled by intermediate (IM) reagents, and the plasma samples were labeled by the heavy reagents. The light, IM and heavy labeled samples
were combined and fractionated into eight fractions by strong cation exchange chromatography and analyzed on an Orbitrap Velos Pro. The average
(and standard deviation) protein concentration of CSF and plasma, age at sampling and ratio male/female of the five patients are presented in the
figure.
doi:10.1371/journal.pone.0090429.g004
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To examine how blood contaminated CSF is affected by
centrifugation, we compared two CSF samples spiked to achieve
0.5% blood where only one was centrifuged (experiment B,
Figure 2). We found that 54 out of 129 quantified proteins
increased more than 1.5 fold in the not-centrifuged sample and
these were regarded as affected by centrifugation (Table S3). More
than 10 fold increase was observed for 20 proteins and among
these were proteins previously suggested as markers for blood
contamination like hemoglobin and carbonic anhydrase 1 and 2
[6]. Our results showed that centrifugation before freezing
removed most of the amount of these proteins.
Proteins affected by the rostro-caudal gradient
In this study we used shotgun and targeted proteomics to
quantify peptides and proteins in seven RCG points ranging from
the 2nd - 45th mL CSF collected by LP from one individual. The
first aim was to examine whether the protein origin (plasma or
CNS) reflects the protein concentration change along the RCG as
previously suggested [11]. Another aim was to explore whether
different sampling volumes of CSF could affect the concentration
of proteins, which is highly relevant in designing proteomic
biomarker studies.
The fold change of the overall protein concentration between
RCG point 1 (the 1-2nd mL) and 7 (the 44-45th mL) was 1.63,
indicating an approximate 60% total protein concentration
decrease from the lumbar towards the ventricular area. These
results show a good linearity with an R-squared value of 0.89
(Figure 5) and correlate to previous studies [14]. To verify the
change in total protein concentration depending on the volume of
CSF collected, the CSF protein concentration between the 1st and
20th mL of the RCG was measured in two new patients (with free
CSF circulation). The fold change of the protein measurements
were 1.3 and 1.45 (data not shown), verifying the trend observed
from the first patient.
A SID-MRM study of 48 proteins (70 peptides) was designed to
further confirm the trend observed during the iTRAQ quantifi-
cation (Table S5). Based on the criteria from Table 1 the proteins
quantified in the two related experiments were again categorized
according to whether they were affected by the RCG or not, in
addition to being classified into CNS-derived (origins from
neurons, glial and leptomeninges) and blood-derived based on
literature mining (Table 2). The results from the iTRAQ and SID-
MRM study showed that plasma-derived proteins increased in
concentration downwards in the RCG whereas there was no
observable abundance change for the CNS-derived proteins. In
both the iTRAQ and SID-MRM study the fold change was found
to be typically around 1.6 for the plasma-derived proteins between
RCG point 1 and 7 (Table S5). Proteins produced in the
leptomeninges such as prostaglandin-H2 D-isomerase, are consid-
ered by others to increase down the RCG due to a constant
production rate. In our experiment we found that prostaglandin-
H2 D-isomerase had a fold change of 1.2 in the MRM and 1.3 in
the iTRAQ study between RCG point 1 and 7, and the protein
was placed in the uncertain group (Table S5). Proteins with mixed
origins such as transthyretin are suggested to increase down the
RCG. With a fold change of 1.2 in the iTRAQ experiment and 1
in the MRM experiment we concluded that there was no
observable change for this protein.
Plasma/CSF protein ratio
Corresponding plasma and CSF samples from five individuals
without neurological symptoms were analyzed by dimethyl-based
shotgun proteomics using an Orbitrap Velos Pro. Our goal was to
obtain estimates on the plasma/CSF ratios for a portion of the
proteins present in these proteomes. This information could be
used to further indicate which CSF proteins that appears to be
affected by or origins from plasma/blood. It will also give
information about these proteins ability to cross the blood-brain
barrier (BBB), and indicate if it would be useful to quantify a given
biomarker candidate protein in both CSF and plasma in a
biomarker verification experiment. Equal total amount of protein
(10 mg) from CSF and plasma was par-wise compared for the five
patients, and the plasma/CSF ratio for each protein was averaged
across the five individuals. From 434 proteins identified across all
experiments (data not shown), 152 proteins were quantified with
two or more unique peptides in two or more individuals (Table
S6). Albumin had an average plasma/CSF ratio of 1.03, ranging
from 0.74 to 1.52 (%CV 35.6) (Table S6). These ratios are based
on comparison of equal total protein amounts of plasma and CSF
proteins. If calculated based on equal volume, the average albumin
plasma/CSF ratio was 177:1. This is in accordance to the
expectation that the plasma to CSF protein concentration is
approximately 200:1. The blood proteins showed a varying
plasma/CSF ratio with distributions from around 1 all the way
to 81. The proteins with the largest plasma/CSF ratio were
fibrinogen, apolipoprotein B-100 and Ig mu chain C region, all
with ratios between 48 and 81, while hemoglobin alpha had a ratio
of about 6. In addition to these proteins, most of the other blood-
derived proteins also appeared to have a higher plasma/CSF ratio
compared to albumin, indicating that they do not cross the blood-
CNS barriers to the same degree as albumin.
Combining the information from the different
experiments
Table S7 combines all the results from the shotgun experiments
described in the three previous sections (Table S2, S3, S4 and S6
combined). All the data can easily be combined since only unique
peptides have been associated with their respective protein
accession numbers. Combining proteomic data in this format is
possible when different search engines have been used since there
will not be any conflict with peptides shared between several
accession numbers leading to protein grouping. The exception
from this is the RCG iTRAQ experiment where protein groups
have been used. When one or more of the peptides map to more
Figure 5. Protein concentration measurement of along the
rostro-caudal gradient. Protein concentration of the cerebrospinal
fluid (CSF)-derived proteins from the seven points along the rostro-
caudal gradient (RCG). The CSF was measured in triplicates with Qubit,
and error bars of the standard deviation are included. R squared value
0.8931.
doi:10.1371/journal.pone.0090429.g005
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Table 2. Categorization of proteins based on fold change, R-squared values and major expected contributing source of origin.
Acc. No Protein ID Category Expected contributor
P01009 Alpha-1-antitrypsin Affected Blood
P02647 Apolipoprotein A-I Affected Blood
P08603 Complement factor H Affected Blood
P00738 Haptoglobin Affected Blood
P02750 Leucine-rich alpha-2-glycoprotein Affected Blood
P04004 Vitronectin Affected Blood
P02768 Serum albumin Affected Blood [9]
P02763 Alpha-1-acid glycoprotein 1 Affected* Blood
P01011 Alpha-1-antichymotrypsin Affected* Blood
P00450 Ceruloplasmin Affected* Blood
P01024 Complement C3 Affected* Blood
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 Affected* Blood
P02743 Serum amyloid P-component Affected* Blood
P01023 Alpha-2-macroglobulin Uncertain Blood
P68871 Hemoglobin subunit beta Uncertain Blood
P02787 Serotransferrin Uncertain Blood
P69905 Hemoglobin subunit alpha Uncertaina Blood
P41222 Prostaglandin-H2 D-isomerase Uncertain CNS (lept.) [9]
P05090 Apolipoprotein D Uncertain Several tissues
P06396 Gelsolin Uncertain Several tissues
P05067 Amyloid beta A4 protein Unaffected Several tissues
P36222 Chitinase-3-like protein 1 Unaffected Several tissues
P10909 Clusterin Unaffected Several tissues
O43505 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase Unaffected Several tissues
Q8WXD2 Secretogranin-3 Unaffected Several tissues
O75326 Semaphorin-7A Unaffected Several tissues
P02649 Apolipoprotein E Unaffected Several tissues
P43121 Cell surface glycoprotein MUC18 Unaffected* Several tissues
P36955 Pigment epithelium-derived factor Unaffected* Blood
P49908 Selenoprotein P Unaffected* Blood
P02766 Transthyretin Unaffected* Both [9]
P01034 Cystatin-C Unaffected CNS (lept.) [9]
O15240 Neurosecretory protein VGF Unaffected CNS/PNS
P51693 Amyloid-like protein 1 Unaffected CNS
Q96GW7 Brevican core protein Unaffected CNS
Q12860 Contactin-1 Unaffected CNS
Q92876 Kallikrein-6 Unaffected CNS
P13591 Neural cell adhesion molecule 1 Unaffected CNS
Q99574 Neuroserpin Unaffected CNS
Q9UHG2 ProSAAS Unaffected CNS
P05060 Secretogranin-1 Unaffected CNS
P13521 Secretogranin-2 Unaffected CNS
P10645 Chromogranin-A Unaffected CNS [31]
Q9P121 Neurotrimin Unaffected CNS [32]
Q99435 Protein kinase C-binding protein NELL2 Unaffected CNS [33]
Q9P0K1 Disintegrin and metalloproteinase domain-containing protein 22 Unaffected* CNS
O95502 Neuronal pentraxin receptor Unaffected* CNS [34]
P04271 Protein S100-B Unaffecteda CNS (brain) [9]
In order to explore how different proteins were affected by the rostro-caudal gradient, we used the fold change and R-squared values of the proteins quantified with
SID-MRM and iTRAQ to categorize the proteins into the three categories: affected by the RCG, unaffected by the RCG and uncertain. The fold change was calculated
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than one accession number, then all these numbers are listed in the
table (column: acc.numbers_RCG_exp.). In cases with a group of
proteins, the leading protein accession number has been aligned
with the corresponding accession numbers from the other
experiments. Proteins with unique peptides and peptides that also
match other accession numbers, are listed as single entries with an
indicator of having shared peptides (column: subgroupNum_RC-
G_exp). This table gives a simple and complete overview of the
proteins we detected in our experiments and whether they are
affected by blood spike–in, centrifugation, RCG, their plasma/
CSF ratio and also how the relation is between the experiments for
each protein.
Suggested biomarker candidates could be affected by
blood contamination
It is known that several neurological disorders lead to impaired
BBB which may cause increased influx of plasma proteins into
CSF, and in addition, CSF can be blood contaminated during LP.
Comparing the list of 201 proteins previously reported to be
differentially abundant in CSF of multiple sclerosis patients
(reviewed in [28]) with the combined list in Table S7 allowed 79
matches. Of these, we found 35 proteins to potentially be affected
by blood contamination, 23 were unaffected and 14 were
uncertain. This indicates that perhaps 50% or more of the
proteins previously reported as candidate biomarkers for multiple
sclerosis are potentially affected by blood contamination, and their
origin, at least in part, could be from plasma. One possible reason
for the high number of apparently plasma-derived proteins being
reported as regulated in multiple sclerosis is that the BBB could be
affected in these patients and this again could influence the degree
of influx of plasma proteins into their CSF.
Discussion
If the concentration of a biomarker candidate is influenced by
blood contamination, then the quantitative measurements of this
protein should be assessed with extra caution. The information
from the blood contamination experiments will be highly relevant
to determine whether blood contaminated CSF samples are
acceptable to be included in a verification study. If your protein of
interest is unaffected by blood contamination, then blood
contaminated samples could potentially still be used in verification
studies of this protein. In relation to this, the results also indicate
which proteins in CSF that origin (fully or partially) from plasma,
and which proteins that appear to be unaffected by blood
contamination and are likely to be CNS-derived. The correct
endogenous amounts of the latter category of proteins could likely
be measured in CSF even if the samples are blood contaminated.
Some of the proteins observed in the unaffected group in Table S2
appeared to decrease in amount after blood spike-in, as 45
proteins had a more than two fold decrease in the samples spiked
to achieve 2% blood. This was however not observed for the
samples spiked to achieve 0.5% blood. Hence, we hypothesize that
the addition of large amounts of blood to the CSF samples and
analysis by label-free shotgun proteomics could lead to suppression
of lower abundant proteins and that their abundances appear to
be lower than they are. One could also envision that the addition
of blood would introduce new proteases that degrade certain
proteins, as has been suggested previously [2,6]. Some proteins are
synthesized locally in the CNS in addition to arising from plasma,
leading to a mixed contribution to the CSF concentration of these
proteins. The ‘‘uncertain’’ category in the blood contamination
experiment (Table S2) is particularly likely to contain such
proteins, as there seems to be some effect of blood contamination
for these proteins, but not sufficient to say for sure that there is an
effect. Even if a protein mainly arises from plasma, its migration
across the BBB might be variable due to inter-individual or disease
related variations in the BBB properties. Hence, for most proteins
detected in both CSF and plasma, it would be useful to measure
the concentration in both fluids. During depletion, proteins not
targeted by the column could be removed due to unspecific
binding to the column or by binding to target proteins. The blood
contamination study included analysis of both depleted (Experi-
ment A) and non-depleted (Experiment B) samples. The informa-
tion in Table S2 and S3 is therefore complementary, and one can
examine if the depletion process has influenced the result or
removed certain proteins by comparing the results in the two
tables.
For the plasma/CSF comparison experiment, a wide range of
ratios were observed as described in the results section. The
reasons for the different plasma/CSF ratios between plasma-
derived proteins remain to be determined, but it has been
suggested that factors like protein size, hydrogen bonds and
hydrodynamic volume are important for a proteins ability to cross
the BBB [29]. Plotting the calculated theoretical MW of the
proteins identified in our experiments against the observed
plasma/CSF ratio did not show any such correlation (data not
shown). The potential ability of the proteins to form multimers/
complexes or being associated to larger structures in blood, like
cells or platelets, was not taken into account, but is likely to be a
main factor in the protein’s ability to cross the BBB. This can be
exemplified with IgM, apolipoprotein B-100, fibrinogen and
haptoglobin which were found to have the highest plasma/CSF
ratios in our experiments (Table S6). Based on the %CV values, it
was also clear that some proteins had a very varying plasma/CSF
ratio between patients (both proteins with high, medium and low
plasma/CSF ratio), whereas other proteins displayed less variation
in their ratio like complement C3 (15%CV in five individuals).
One reason for this could be corresponding variations in plasma of
these proteins, but this was not further examined. Of the proteins
with plasma/CSF ratio below 0.2, the majority appeared to be
CNS-derived proteins like contactin-1 and prostaglandin-H2 D-
isomerase, and the contribution of plasma to the CSF concentra-
tion of proteins with such low ratios appears to be small.
In theory, the higher the plasma/CSF ratio of a protein, the
more influence will the blood contamination have on the CSF
concentration. Exceptions would be if there is high intrathecal
synthesis of the protein, particularly in combination with low
plasma concentrations. As can be observed from Table S7, several
of the proteins with high plasma/CSF ratios increase more than
five fold from regular CSF to CSF spiked to achieve 2% blood.
This includes serum amyloid P-component (11 fold), apolipopro-
tein C-II (51 fold), apolipoprotein C-III (31 fold) and apolipopro-
tein M (11 fold). Hence, care should be taken when it comes to
interpreting the CSF concentration of proteins with high plasma/
between the 1-2nd and 44-45th mL of CSF (referred to as RCG point 1 and 7), and the classification was based on the criteria from Table 1.The proteins are also
categorized into groups based on the major expected contributing source of origin, with Uniprot as the primary reference unless otherwise stated. See Table S5 for
details. The asterisk (*) marks conflicting results: affected + unaffected = uncertain; affected + uncertain = affected; unaffected + uncertain = unaffected. Proteins only
quantified in the SID-MRM study is marked with a.
doi:10.1371/journal.pone.0090429.t002
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CSF ratios, as their CSF concentration appears to be very sensitive
to blood contamination.
For the RCG study, the plasma proteins show an increase in
concentration towards the lumbar area and steady influx due to
diffusion laws are believed to be the cause of this gradient. In
contrast to Reiber et al. [9], we found none of the selected brain-
derived proteins to increase or decrease towards the lumbar area.
Our findings are in agreement with the recent publication by
Brandner et al. [12], where they found that the two CNS-derived
proteins S100B and NSE did not decrease from ventricular to
lumbar CSF in seven patients with free CSF circulation. Reiber
described an increase in concentration in proteins that origins
from the leptomeninges that surrounds the spinal cord [9] which
was confirmed by Brandner et al, using prostaglandin-H2 D-
isomerase. Compared to their study, we found the RCG effect on
prostaglandin-H2 D-isomerase to be uncertain with a fold change
of 1.3 from the first to seventh RCG point. In addition, we verified
our iTRAQ results using SID-MRM and included several other
brain-derived proteins such as chitinase 3-like protein, secreto-
granin-3 and S100B and found that none of them decreased down
the RCG. Hence, from our results it seems like the concentration
of the brain-derived proteins is not affected by the RCG. It should
be pointed out that we studied this effect in one patient only, a PSP
patient, and examined CSF up to the 44th collected mL which is a
limitation of this work. However, our results are supported by the
findings by Brander et al. [12]. It was also evident from their study
as well as ours, that the plasma proteins showed a concentration
increase towards the lumbar area. In our study, one could perhaps
argue that the gradient is a result of blood entering the sample
during LP. However, since the concentration of hemoglobin drops
substantially from RGC point 1 to 2, while other high abundant
blood proteins such as haptoglobin and fibrinogens are close to
linear over the seven RCG points, it strengthens our theory of a
gradient. The gradient was also confirmed in two other patients
where there was a 30 and 45% change in total protein
concentration from the 1st to the 20th mL CSF collected. It
therefore seems apparent that the collected volume of CSF affects
the protein concentration, and most importantly, that the brain-
derived proteins does not appear to be affected. Whether this is
true for all conditions and diseases needs to be further tested.
Given the linearity for the plasma proteins in the RCG and that
there is a 1.6 fold change (60%) between RCG point 1 (the 1-2nd
mL CSF) and 7 (the 44-45th mL CSF), it will be approximately
30% difference in concentration for the plasma proteins if only
1 mL CSF is collected compared to if all 45 milliliters are collected
as one sample. In clinical practice between 5 and 20 milliliters of
CSF are normally collected, which would give a range of
approximately 10-15% variation in the plasma protein concen-
trations based on the results obtained from our examined patient.
This number will, as we have shown, vary from patient to patient,
and the effect should be examined in a larger number of patients
to get a clear picture of the variation.
When combining the results from all three experimental
sections (Table S7) we observed that there is a good correlation
between which proteins that were affected by blood spike-in, those
that were affected by the RCG and those with relatively high
plasma/CSF ratios (. 0.4). There was also a very good correlation
between the proteins that were unaffected by both the blood spike-
in and the RCG and those with lower plasma/CSF ratios (, 0.2).
These observed correlations strengthen the results and conclusions
from the individual experiments, and shows that the experiments
give complementary but also related information.
Conclusion
When proteins with high plasma/CSF ratio appear as
differentially expressed in CSF-based proteomics experiments,
one should strongly consider the chance of this being due to blood
contamination. The majority of the CNS-derived proteins in CSF
were not affected by blood contamination and the concentration
of these proteins could be measured in blood contaminated
samples. Most of these proteins also appeared to be unaffected by
the RCG, so the volume of CSF collected would not influence the
concentration of these proteins in CSF.
The majority of proteins previously suggested as markers for
blood contamination, are largely removed from CSF during
centrifugation. If the concentration of a detected biomarker
candidate is influenced by blood contamination and/or the RCG,
then the results should be assessed with this in mind. In addition,
the results indicate proteins in CSF which likely arise (fully or
partially) from plasma, which is useful information when
determining if the concentration of a given CSF biomarker
candidate also should be assessed in plasma. In sum, our study
gives important information about the influence of factors like
blood contamination, RCG and BBB on protein concentration
measurements in CSF, particularly important in the field of
biomarker discovery, but also for routine clinical measurements. A
limitation of our work is the low number of samples included, and
future studies including larger number of samples should be
conducted to verify our findings.
Supporting information
The mass spectrometry proteomics data from the blood
contamination and RCG discovery studies have been deposited
to the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository [30] with
the dataset identifier PXD000401.
Supporting Information
Document S1 In-solution digestion protocol.
(PDF)
Table S1 Peptides used for quantification in the RCG
verification study. The table contains protein ID, Uniprot
accession number, peptide sequence, transition used for quanti-
fication, precursor m/z (Q1) and fragment m/z (Q3) of the
endogenous and SIS peptides, and collision energy used in the
MRM assay. a indicate that the peptides were of AQUA quality.
(PDF)
Table S2 Results from the blood contamination study,
experiment A. Proteins from the blood contamination study A
(SDS-PAGE label free using Progenesis and analyzed using the
database homo sapiens, SwissProt) quantified with two or more
peptides. CS is the confidence score of the proteins, obtained in
the Progenesis LC software. The ratios for 0.5% blood/reference
CSF, 2% blood/reference CSF and 0.5% blood/2% blood are
calculated. Proteins with ratio .1.5 in either of the two spike-in
levels were classified as affected (n = 262). Ratio ,1.2 was
classified as not affected (n = 403) and ratios in between were
uncertain (n = 149). The protein and peptide reports from
Progenesis are available in the table.
(XLSX)
Table S3 Results from the blood contamination study,
experiment B. Comparison of the effect of centrifugation of
0.5% blood contaminated CSF with label free quantification.
Ratio .1.5 for 0.5% blood not centrifuged/0.5% blood
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centrifuged were considered affected by blood contamination,
while ratio ,1.2 was considered as unaffected. CS is the
confidence score from the Progenesis output. The data are
identified using the database homo sapiens, SwissProt. The protein
and peptide reports from Progenesis are available in the table.
(XLSX)
Table S4 Results from the rostro caudal gradient
discovery study. Results from the iTRAQ discovery experiment
applied on the seven RCG points of CSF. Proteins were quantified
using Spectrum Mill and identified using homo sapiens, SwissProt.
The table lists identification and quantification of 279 proteins
with two unique peptides or more with R square value calculated
of the seven RCG points, and the fold change (FC) of the 1-2nd
and 44-45th mL, corresponding to RCG point 1 and 7. Included in
the table is also R squared value of the six RCG points from the
10-11th to the 44-45th mL and the FC between the 10-11th and 44-
45th mL (RCG point 2 and 7). The proteins were considered
affected or not according to the criteria in Table 1 (also shown in
this table under criteria). The protein and peptide reports from
Spectrum Mill are available in this table, in addition to a matrix
explaining the combination and labeling of experiments 1-3 and a
summary of proteins identified with $2 peptides.
(XLSX)
Table S5 Comparison of the R-squared values and fold
changes for the peptides quantified with SID-MRM and
the iTRAQ experiment for the RCG study. Proteins are
categorized into groups based on the major expected contributing
source of origin, Uniprot is the primary reference unless otherwise
stated.
(XLSX)
Table S6 Results from the plasma/CSF study. Results
from the plasma/CSF study (n = 5 patients, P1-P5). The proteins
are quantified using dimethyl labeling in Proteome Discoverer
(PD), identified using Mascot and the homo sapiens database from
SwissProt. The average protein ratio, in addition to standard
deviation and %CV are included for each protein. The protein
and peptide reports from PD are available in the table.
(XLSX)
Table S7 Summary of Table S2, S3, S4 and S6. This
combined table gives an overview over which proteins that are
affected by blood spike-in, centrifugation, RCG and their plasma/
CSF ratio, and also how the relation is between the experiments
for each protein. The proteins are combined based on accession
numbers, except for the iTRAQ discovery study where the leading
protein was used.
(XLSX)
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